TrialBreast cancer research : BCR2020

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.

Johannes Ettl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.